California is currently home to 5595 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium
Recruiting
The objective is to evaluate the safety and efficacy of low dose and high dose CBT-001 eye drop dosed twice daily for 24 months compared to vehicle in reducing conjunctival hyperemia and preventing pterygium progression in eyes with pterygia.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/29/2024
Locations: Bakersfield Eye Institute, Bakersfield, California
Conditions: Pterygium
A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
Recruiting
This study is a Phase I/II open-label, multi-center study to evaluate the safety, tolerability, PK, and an anti-tumor activity of JIN-A02, a 4th generation EGFR-TKI agent for oral administration, in EGFR mutant-positive, advanced NSCLC subjects who showed disease progression after receiving standard anticancer therapy, including approved EGFR-TKI therapy and/or no more than a single platinum-based anticancer chemotherapy. In Part A of the study, dose escalation is carried out where MTD is evalua... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/29/2024
Locations: Chao Family Comprehensive Cancer Center, University of California Irvine Healthcare, Orange, California
Conditions: EGFR Mutant Advanced Non-small Cell Lung Cancer
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
Recruiting
This phase II trial studies the effect of the combination of ramucirumab and trifluridine/tipiracil or paclitaxel in treating patients with previously treated gastric or gastroesophageal junction cancer that has spread to other places in the body (advanced). Ramucirumab may damage tumor cells by targeting new blood vessel formation. Trifluridine/tipiracil is a chemotherapy pill and that may damage tumor cells by damaging their deoxyribonucleic acid (DNA). Paclitaxel may block cell growth by stop... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/29/2024
Locations: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Unresectable Gastric Adenocarcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
Recruiting
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).
Gender:
ALL
Ages:
21 years and above
Trial Updated:
03/28/2024
Locations: The Regents of the University of California, San Diego, La Jolla, California
Conditions: AAA, AAA - Abdominal Aortic Aneurysm
Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening
Recruiting
This study is part of the development and validation of a non-invasive lung screening test which aim to identify early stage lung cancer in patients at high risk for lung cancer.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
03/28/2024
Locations: Scripps Memorial Hospital, Encinitas, California
Conditions: Lung Cancer
Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects
Recruiting
This is a phase 1, multicenter, open-label, multiple-ascending dose study to evaluate the safety, pharmacokinetics and clinical activity of KPG-818 in subjects with hematological malignancies. Approximately 30 patients will be enrolled for dose escalation of 4 dose levels. Indication: Hematological malignancies (multiple myeloma \[MM\], mantle cell lymphoma \[MCL\], diffuse large B-cell lymphoma \[DLBCL\], adult T-cell leukemia-lymphoma \[ATL\], and indolent non Hodgkin lymphomas such as follic... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2024
Locations: UC Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Hematological Malignancies
Cold Agglutinin Disease Real World Evidence Registry
Recruiting
This is a multinational, multi-center, observational, prospective, longitudinal disease registry designed to collect data on participants with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS). Among them, a minimum of 30 patients with CAD treated with sutimlimab are expected to take part in the sutimlimab cohort study. Patients with CAD who have been enrolled in previous sutimlimab clinical trials (e.g., BIVV009-01/LTS16214 \[NCT02502903,CAD patients\], BIVV009-03/EFC16215 \[NCT03... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: SLO Oncology and Hematology Site Number : 1235, San Luis Obispo, California
Conditions: Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS)
PRT for Adolescents With High Functioning Autism
Recruiting
The purpose of this study is to identify improvement in behavioral and social function and changes in the brain following Pivotal Response Treatment (PRT) for Adolescents in highly verbal adolescents with autism spectrum disorder (ASD).
Gender:
ALL
Ages:
Between 11 years and 14 years
Trial Updated:
03/26/2024
Locations: Stanford Research Park, Palo Alto, California
Conditions: Autism, Autism Spectrum Disorder High-Functioning, Developmental Disability, Child Development, Behavior, Child, Behavior, Social
Breast Cancer Survivorship Biorepository
Recruiting
This study collects blood samples as well as clinical and self-report data from stage I-III breast cancer survivors to create a biorepository for future use. The creation of this biorepository will allow for future research into links between individual, molecular, and genomic signatures and cancer outcomes.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Recruiting
The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Stanford Cancer Institute, Stanford, California
Conditions: Prostatic Neoplasms, Castration-Resistant
Platelet Rich Plasma Testis Treatment for Infertile Men
Recruiting
Investigate the effect of intratesticular injection of autologous platelet rich plasma (PRP) on sperm retrieval rates and IVF outcomes in infertile men who already underwent a negative sperm retrieval. Currently, there is no alternative treatment after failed TESE. Prior series suggest that intratesticular PRP injections may improve TESE outcomes. We hope to determine whether PRP is an effective treatment for this patient population.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: Stanford Urology Clinic, Stanford, California
Conditions: Male Infertility, Nonobstructive Azoospermia, Azoospermia
Double-S: a Wearable Device for Erectile Dysfunction
Recruiting
The purpose of this study is to use a minimally invasive erectile device for patients suffering from erectile dysfunction.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: Stanford Healthcare, Stanford Hospital, Stanford, California
Conditions: Erectile Dysfunction